OssulinTM, a Novel Oral Insulin Product, Shows Promising Bioavailability for Advancing Diabetes Therapy
* Reuters is not responsible for the content in this press release.
http://www.businesswire.com/news/home/20091109005245/en Data Presented at San Francisco Diabetes Conference LONDON--(Business Wire)-- New data from Puredel Limited, presented at the 9th Annual Diabetes Technology Meeting in San Francisco, CA, suggests that higher blood levels of insulin were achieved by Ossulin than had been previously demonstrated by other oral products. In a series of experiments covering a range of doses and models, Ossulin consistently delivered around 20% of the insulin dose into the bloodstream. The authors concluded that: "Ossulin provides an efficient way to deliver insulin to the body via oral administration, resulting in blood levels higher than those previously observed with other oral insulin products." Lead author and Chief Scientific Officer for Puredel, Dr. Marco Prosdocimi added: "Oral insulin could represent a major advance in diabetes therapy through its simplicity of use, and because it mimics the natural physiological route of the hormone. The incorporation of insulin into the proprietary delivery agent NatsomTM gives rise to a product which is not destroyed by the gastric environment." About Puredel Limited Puredel is focusing its research on the development of Ossulin, which has shown promising results in preliminary studies. Puredel will also explore other target molecules which are currently injected, and whose oral administration would greatly improve patient convenience and compliance. Natreon`s R&D staff and facilities in the United States and India are working closely with Puredel to help facilitate the next stage of scientific validation prior to commercial development. Puredel will coordinate the product development of Ossulin up to proof of clinical efficacy, drawing on its extensive network of scientific experts in Europe and North America. For further information and a copy of the abstract, please contact: Stephen Appelbee, CEO, CM&D Pharma Limited +44 20 7259 8488 appelbee@cmdpharmaltd.com www.cmdpharmaltd.com CM&D Pharma Limited Stephen Appelbee, CEO, +44 20 7259 8488 appelbee@cmdpharmaltd.com www.cmdpharmaltd.com Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters